EGFR and non-small cell lung carcinoma: These trials conflict with the majority of evidence evaluating the use of ICIs in EGFRm patients, showing no benefit to the addition of an ICI in metastatic EGFRm NSCLC, for example, the second-line Checkmate 722 study, where no benefit was seen with the addition of nivolumab to chemotherapy after EGFR-directed TKI, and a metanalysis investigating ICI use vs. docetaxel in second-line trials (Keynote 010, OAK, POPLAR, Checkmate 017 and Checkmate 057) (Table 1) [47,57].